Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitor therapy has been rapidly developed for the treatment of unresectable hepatocellular carcinoma (HCC). In the IMbrave150 trial, atezolizumab plus bevacizumab was seen as the first-line systemic drug therapy for unresectable HCC because overall survival and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Shigeki, Kawaoka, Tomokazu, Yamasaki, Shintaro, Johira, Yusuke, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Amioka, Kei, Naruto, Kensuke, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Tsuge, Masataka, Teraoka, Yuji, Kouno, Hirotaka, Takaki, Shintaro, Mori, Nami, Tsuji, Keiji, Oka, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670624/
https://www.ncbi.nlm.nih.gov/pubmed/38001666
http://dx.doi.org/10.3390/cancers15225406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670624/
https://www.ncbi.nlm.nih.gov/pubmed/38001666
http://dx.doi.org/10.3390/cancers15225406

Ejemplares similares